Literature DB >> 22115556

Compatibility of the linear-quadratic formalism and biologically effective dose concept to high-dose-per-fraction irradiation in a murine tumor.

Shinya Otsuka1, Yuta Shibamoto, Hiromitsu Iwata, Rumi Murata, Chikao Sugie, Masato Ito, Hiroyuki Ogino.   

Abstract

PURPOSE: To evaluate the compliance of linear-quadratic (LQ) model calculations in the high-dose range as used in stereotactic irradiation in a murine tumor model. METHODS AND MATERIALS: Female 10-week-old Balb/c mice bearing 1-cm-diameter EMT6 tumors in the hind legs were used. Single doses of 10-25 Gy were compared with 2-5 fractions of 4-13 Gy given at 4-hour intervals. Cell survival after irradiation was determined by an in vivo-in vitro assay. Using an α/β ratio determined for in vitro EMT6 cells and the LQ formalism, equivalent single doses for the hypofractionated doses were calculated. They were then compared with actually measured equivalent single doses for the hypofractionated doses. These fractionation schedules were also compared simultaneously to investigate the concordance/divergence of dose-survival curves plotted against actual radiation doses and biologically effective doses (BED).
RESULTS: Equivalent single doses for hypofractionated doses calculated from LQ formalism were lower than actually measured doses by 21%-31% in the 2- or 3-fraction experiments and by 27%-42% in the 4- or 5-fraction experiments. The differences were all significant. When a higher α/β ratio was assumed, the discrepancy became smaller. In direct comparison of the 2- to 5-fraction schedules, respective dose-response curves almost overlapped when cell survival was plotted against actual radiation doses. However, the curves tended to shift downward by increasing the fraction number when cell survival was plotted against BED calculated using an α/β ratio of 3.5 Gy for in vitro EMT6 cells.
CONCLUSION: Conversion of hypofractionated radiation doses to single doses using the LQ formalism underestimated the in vivo effect of hypofractionated radiation by approximately 20%-40%. The discrepancy appeared to be larger than that seen in the previous in vitro study and tended to increase with the fraction number. BED appeared to be an unreliable measure of tumor response.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22115556     DOI: 10.1016/j.ijrobp.2011.05.034

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  13 in total

1.  Hypofractionated stereotactic radiotherapy for brain metastases from lung cancer : Evaluation of indications and predictors of local control.

Authors:  Takeaki Ishihara; Kazunari Yamada; Aya Harada; Kenta Isogai; Yoshihiro Tonosaki; Yusuke Demizu; Daisuke Miyawaki; Kenji Yoshida; Yasuo Ejima; Ryohei Sasaki
Journal:  Strahlenther Onkol       Date:  2016-05-11       Impact factor: 3.621

2.  Applicability of the linear-quadratic model to single and fractionated radiotherapy schedules: an experimental study.

Authors:  Akifumi Miyakawa; Yuta Shibamoto; Shinya Otsuka; Hiromitsu Iwata
Journal:  J Radiat Res       Date:  2013-12-17       Impact factor: 2.724

3.  A matter of timing: identifying significant multi-dose radiotherapy improvements by numerical simulation and genetic algorithm search.

Authors:  Simon D Angus; Monika Joanna Piotrowska
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

4.  Compatibility of the repairable-conditionally repairable, multi-target and linear-quadratic models in converting hypofractionated radiation doses to single doses.

Authors:  Hiromitsu Iwata; Naruhiro Matsufuji; Toshiyuki Toshito; Takashi Akagi; Shinya Otsuka; Yuta Shibamoto
Journal:  J Radiat Res       Date:  2012-10-16       Impact factor: 2.724

Review 5.  Treatment of Breast and Prostate Cancer by Hypofractionated Radiotherapy: Potential Risks and Benefits.

Authors:  K J Ray; N R Sibson; A E Kiltie
Journal:  Clin Oncol (R Coll Radiol)       Date:  2015-03-07       Impact factor: 4.126

6.  Three-fraction CyberKnife radiotherapy for brain metastases in critical areas: referring to the risk evaluating radiation necrosis and the surrounding brain volumes circumscribed with a single dose equivalence of 14 Gy (V14).

Authors:  Hiroshi K Inoue; Ken-Ichi Seto; Akihiko Nozaki; Kota Torikai; Yoshiyuki Suzuki; Jun-Ichi Saitoh; Shin-Ei Noda; Takashi Nakano
Journal:  J Radiat Res       Date:  2013-02-11       Impact factor: 2.724

7.  Five-fraction CyberKnife radiotherapy for large brain metastases in critical areas: impact on the surrounding brain volumes circumscribed with a single dose equivalent of 14 Gy (V14) to avoid radiation necrosis.

Authors:  Hiroshi K Inoue; Hiro Sato; Ken-ichi Seto; Kota Torikai; Yoshiyuki Suzuki; Jun-ichi Saitoh; Shin-ei Noda; Takashi Nakano
Journal:  J Radiat Res       Date:  2013-11-01       Impact factor: 2.724

Review 8.  Radiobiology of radiosurgery for the central nervous system.

Authors:  Antonio Santacroce; Marcel A Kamp; Wilfried Budach; Daniel Hänggi
Journal:  Biomed Res Int       Date:  2013-12-29       Impact factor: 3.411

Review 9.  Radiotherapy and the tumor stroma: the importance of dose and fractionation.

Authors:  Turid Hellevik; Iñigo Martinez-Zubiaurre
Journal:  Front Oncol       Date:  2014-01-21       Impact factor: 6.244

Review 10.  Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules?

Authors:  Yuta Shibamoto; Akifumi Miyakawa; Shinya Otsuka; Hiromitsu Iwata
Journal:  J Radiat Res       Date:  2016-03-22       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.